A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study With a Long-Term Extension Treatment Period to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants With Early Alzheimer's Disease
Latest Information Update: 23 Jul 2024
At a glance
- Drugs Posdinemab (Primary)
- Indications Alzheimer's disease; Cognition disorders; Dementia
- Focus Therapeutic Use
- Acronyms Autonomy
- Sponsors Janssen Research & Development; Janssen-Cilag
- 18 Jun 2024 Planned primary completion date changed from 28 Nov 2025 to 27 Feb 2026.
- 15 May 2024 Planned primary completion date changed from 7 Mar 2025 to 28 Nov 2025.
- 30 Jan 2024 Planned End Date changed from 1 Dec 2025 to 30 Dec 2032.